Cd4 cre 02207129

Mice of both sexes aged 6-12 weeks were used for all experiments. Littermate controls were used whenever possible. Randomization and blinding were not performed. Rosa26^LSL-ITK-SYK mice8 (link) were backcrossed for more than 12 generations on a C57BL/6 genetic background. CD4Cre-ER^T210 (link) mice were crossed to the Rosa26^LSL-ITK-SYK strain to generate the ITK-SYK^CD4Cre-ERT2 mice. Rosa26^LSL-PB mice16 (link) were crossed to Rosa26^LSL-ITK-SYK mice to generate the Rosa26^LSL-ITK-SYK;Rosa26^LSL-PB strain, and ATP2-H3214 (link) mice were crossed to CD4-Cre mice to generate the ATP2;CD4-Cre transgenic animals. Both resulting lines were crossed again to generate the quadruple-transgenic Rosa26^LSL-ITK-SYK;Rosa26^LSL-PB;ATP2;CD4-Cre mice and control cohorts. C57BL/6, NOD/SCID Il2rg^-/- (NSG, 005557), CD4-Cre (02207129 (link)) and PD-1^-/- (02827623 (link)) mice were purchased from the Jackson Laboratory, Bar Harbor, Maine, USA. CD4-Cre and PD-1^-/- mice were backcrossed on a C57BL/6 genetic background. All animal experiments were performed according to local guidelines (Regierung von Oberbayern, Munich, Germany). Mice were euthanized if they exhibited signs of lymphoma (lymph node enlargement, palpable tumour, laboured breathing, ascites) or if they lost 20% or more of their body weight. None of the approved thresholds were exceeded at any time.